Bellerophon Therapeutics, Inc. (BLPH): Price and Financial Metrics


Bellerophon Therapeutics, Inc. (BLPH)

Today's Latest Price: $13.38 USD

0.28 (-2.05%)

Updated Jun 2 2:32pm

Add BLPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

BLPH Daily Price Range
BLPH 52-Week Price Range

BLPH Stock Price Chart More Charts


BLPH Price/Volume Stats

Current price $13.38 52-week high $26.00
Prev. close $13.66 52-week low $3.19
Day low $13.20 Volume 172,942
Day high $13.70 Avg. volume 666,196
50-day MA $14.05 Dividend yield N/A
200-day MA $8.54 Market Cap 82.05M

Bellerophon Therapeutics, Inc. (BLPH) Company Bio


Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is founded in Warren, New Jersey.


BLPH Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BLPH Latest Social Stream


Loading social stream, please wait...

View Full BLPH Social Stream

Latest BLPH News From Around the Web

Below are the latest news stories about Bellerophon Therapeutics Inc that investors may wish to consider to help them evaluate BLPH as an investment opportunity.

Alan Fournier Adds 4 Stocks to Portfolio

Guru releases 1st-quarter portfolio Continue reading...

Yahoo | May 29, 2020

Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

Bellerophon intends to use the net proceeds from the Offerings, together with its current cash and cash equivalents, for funding its ongoing clinical trials, working capital needs and other general corporate purposes. A total of 3,365,384 shares of common stock were issued in the Offerings, which includes the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $13.00 per share. Jefferies LLC acted as sole book-running manager for the Underwritten Offering.

Yahoo | May 22, 2020

8 Biotechs Tapping Secondary Markets for $3 Billion

Company stocks drop on dilution, but monies could benefit shareholders down the line Continue reading...

Yahoo | May 19, 2020

Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

WARREN, N.J., May 19, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of.

Yahoo | May 19, 2020

Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

All of the shares in the offering are to be sold by Bellerophon. Bellerophon also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. Bellerophon expects to use the net proceeds from this offering, together with its existing cash and cash equivalents, for funding its ongoing clinical trials, for working capital and general corporate purposes.

Yahoo | May 18, 2020

Read More 'BLPH' Stories Here

BLPH Price Returns

1-mo -15.85%
3-mo 61.40%
6-mo 122.94%
1-year 46.88%
3-year -29.21%
5-year -89.97%
YTD 155.08%
2019 -56.29%
2018 -68.99%
2017 396.15%
2016 -82.43%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7829 seconds.